Cargando…

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus

Detalles Bibliográficos
Autor principal:	Kim, Ji Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543193/ https://www.ncbi.nlm.nih.gov/pubmed/26301191 http://dx.doi.org/10.4093/dmj.2015.39.4.304

Ejemplares similares

Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
por: Yang, Hae Kyung, et al.
Publicado: (2015)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wang, Qiu, et al.
Publicado: (2021)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
por: Murai, Kazuki, et al.
Publicado: (2014)

Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus
por: Ojha, Ashutosh, et al.
Publicado: (2019)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
por: Kim, Soon Ae, et al.
Publicado: (2011)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wan, Heng, et al.
Publicado: (2016)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Sitagliptin Improves Postprandial Hyperglycemia by Inhibiting Glucagon Secretion in Werner Syndrome With Diabetes
por: Watanabe, Kaneyuki, et al.
Publicado: (2013)

Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
por: Lee, Chi-Ho, et al.
Publicado: (2022)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
por: Le, Tuan Dinh, et al.
Publicado: (2020)

Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes
por: Shankar, R Ravi, et al.
Publicado: (2016)

Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis
por: Mita, Tomoya, et al.
Publicado: (2017)

Challenges of optimizing insulin therapy for patients with type 2 diabetes mellitus
por: Yen, Fu‐Shun, et al.
Publicado: (2021)

Self-Monitoring of Blood Glucose in Patients with Insulin-Treated Type 2 Diabetes Mellitus
por: Kim, Kyung-Soo
Publicado: (2018)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus
por: Hattori, Sachiko
Publicado: (2021)

Effects of a d-Xylose Preload With or Without Sitagliptin on Gastric Emptying, Glucagon-Like Peptide-1, and Postprandial Glycemia in Type 2 Diabetes
por: Wu, Tongzhi, et al.
Publicado: (2013)

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
por: Philis-Tsimikas, A, et al.
Publicado: (2013)

Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients
por: Lee, Minyoung, et al.
Publicado: (2019)

Insulin and glucagon secretions, and morphological change of pancreatic islets in OLETF rats, a model of type 2 diabetes mellitus.
por: Hong, Eun Gyoung, et al.
Publicado: (2002)

Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
por: Iwamoto, Yuichiro, et al.
Publicado: (2022)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
por: Shin, Sooyoung, et al.
Publicado: (2016)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus
por: Zykov, Vladislav A, et al.
Publicado: (2018)

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus
por: Chung, Hye Soo, et al.
Publicado: (2011)

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
por: Fukuda, Masahiro, et al.
Publicado: (2018)

Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus
por: Kim, Ji Yoon, et al.
Publicado: (2023)

The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis
por: Mita, Tomoya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qftcmmenepdb2taoohtd1646n3